LY3971297 for Heart Failure

This trial aims to assess how well the new treatment, LY3971297, is tolerated by individuals with heart failure. It targets two types of heart failure: HFpEF, where the heart pumps normally but still doesn't function well, and HFrEF, where the heart doesn't pump as strongly as it should. The trial will compare the effects of the drug and a placebo (inactive substance) across different groups. Ideal participants have experienced stable heart failure symptoms and have been on consistent heart failure medication for at least six months. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial requires that you have been on a stable dose of your heart failure medications for at least 4 weeks before screening and that you do not plan to change your medications during the study. You must also avoid starting any new prescription or nonprescription drugs during the trial.

Research has shown that LY3971297 has been tested in both healthy individuals and those with obesity to assess its tolerability. Earlier studies examined the drug's side effects when administered as an injection under the skin. Results indicated that LY3971297 was generally well-tolerated, with most side effects being mild, such as minor reactions at the injection site.

Unlike the standard treatments for heart failure, which typically include medications like ACE inhibitors, beta-blockers, and diuretics, LY3971297 offers a unique approach. Researchers are excited about LY3971297 because it is administered either subcutaneously (SC) or intravenously (IV), which could offer flexibility and convenience in its delivery method. Additionally, LY3971297 might feature a novel mechanism of action targeting pathways not addressed by existing medications, potentially leading to improved outcomes for patients with heart failure. These features make LY3971297 a promising candidate for addressing unmet needs in heart failure treatment.

Research has shown that LY3971297 mimics a natural hormone that helps lower blood pressure and may improve heart health. Although limited information exists on its effectiveness for heart failure in people, its mechanism suggests it could help manage heart-related symptoms. Early studies in healthy and overweight individuals are examining its safety and how the body processes the drug. This trial will evaluate LY3971297 in various treatment arms to further explore its potential for treating heart failure. More research is needed to confirm its effectiveness.¹²³⁴⁵